“It is your responsibility to be the patient’s advocate,” one expert explained. “We, as the nurses and technologists, have to speak up when we see something that isn’t right.”

The Class I recall includes more than 26,000 vascular stents from Boston Scientific. These devices have been linked to a risk of potential resistance when the stent delivery system is being withdrawn. 

When patients present with STEMI-related cardiogenic shock, treatment with the Impella CP appears to make a positive impact that lasts for at least a decade.

This year marks the 37th annual gathering of the popular Transcatheter Cardiovascular Therapeutics conference. What started as a small gathering in 1988 has grown into one of interventional cardiology’s biggest events.

As mitral transcatheter edge-to-edge repair continues to gain momentum in the United States, a new study of CMS data examines what happens to patient outcomes when the procedure fails.

The balloon-free catheter, which already had a successful launch in the United States, has been associated with positive outcomes and the ability to reach certain lesions more accurately than balloon-based IVL platforms.

Transcatheter patent ductus arteriosus (PDA) closure has been a mainstay in congenital interventional cardiology for decades, but changes in the standard of care have resulted in catheter-based treatments overtaking surgical procedures. 

Though just a small, single-facility study, these findings help care teams know what to look for when performing transcatheter tricuspid valve replacement.

Hypertension is a significant issue in Japan, impacting an estimated 43 million adults. Medtronic's Symplicity Spyral RDN system is now approved for the treatment of those patients. 

Collet, known globally for his dedication to innovation, is the organization's new director of cardiovascular imaging, physiology and translational therapeutics.